There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alnylam Pharma (NASDAQ:ALNY), Vanda (NASDAQ:VNDA) and Johnson & Johnson (NYSE:JNJ) with bullish sentiments.
Alnylam Pharma (ALNY)
In a report issued on October 16, Do Kim from BMO Capital maintained a Buy rating on Alnylam Pharma, with a price target of $124. The company’s shares closed yesterday at $81.26, close to its 52-week low of $78.85.
According to TipRanks.com, Kim is a 4-star analyst with an average return of 14.9% and a 51.3% success rate. Kim covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, Vertex Pharmaceuticals, and Akcea Therapeutics Inc.
Currently, the analyst consensus on Alnylam Pharma is a Strong Buy with an average price target of $146.69, implying an 80.5% upside from current levels. In a report issued on October 3, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $135 price target.
.
See today’s analyst top recommended stocks >>
Vanda (VNDA)
Citigroup analyst Joel Beatty maintained a Buy rating on Vanda on October 16 and set a price target of $31. The company’s shares closed yesterday at $22.73, close to its 52-week high of $23.50.
According to TipRanks.com, Beatty is a 4-star analyst with an average return of 10.0% and a 45.8% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Syndax Pharmaceuticals Inc, and Catabasis Pharmaceuticals.
Currently, the analyst consensus on Vanda is a Strong Buy with an average price target of $27.57, which is a 21.3% upside from current levels. In a report issued on October 3, Oppenheimer also assigned a Buy rating to the stock with a $29 price target.
.
Johnson & Johnson (JNJ)
Raymond James analyst Jayson Bedford maintained a Buy rating on Johnson & Johnson yesterday and set a price target of $149. The company’s shares closed yesterday at $139.46.
According to TipRanks.com, Bedford is a top 25 analyst with an average return of 25.2% and a 79.5% success rate. Bedford covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Stryker Corporation, and BioTelemetry.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Johnson & Johnson with a $151.80 average price target, an 8.8% upside from current levels. In a report issued on October 12, Credit Suisse also maintained a Buy rating on the stock with a $149 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
